Today's session generated a bearish divergence on CCI. I am still bullish, but always ready for a trend retracement on the 20 EMA Line. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own...
If you like this idea, don't forget to support it clicking the Like Button! Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third...
Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm...
After the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is...
Women's healthcare company - Lots of upcoming catalysts through 2020. New acquisition this week of Microchips. Could see this fall to .50s if earnings are garbage - which is definitely a possibility, but target is still $2-$3 next year. This is speculative, but I will hold 5k shares from .79 avg.
Good spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). I was waiting for today's opening to confirm a bullish position. Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89). Disclosure: My ideas contain statements and projections based on...
After the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an...
Stochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force. Please note that biotech companies present high uncertainty. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore...
Xbrane Biopharma AB is a biotechnology company which develops and manufactures biosimilars. Xbrane has a patented protein production platform and world-leading expertise within biosimilar development. Xbrane’s headquarter is located in Solna, just outside of Stockholm, and the company has research and development facilities in Sweden and in Italy. Biosimilars...
Biotechnology stocks surged in the fourth quarter thanks to some takeovers and buyers returning to the health-care sector. Amgen is the biggest of all the biotechs with $144 billion of market cap. It's also one of the few big names that's broken out to new highs. (Along with Vertex .) AMGN's been climbing a wall of worry about competition since the summer....
Stock is making higher lows, finding resistance at the $9 level. Awaiting data for Phase 3 trial. killcvmshorts.com for more information. HIGH reward. All or nothing. Looking good for a long setup.
Since October, shares of APTOSE BIOSCIENCES INC - NASDAQ:APTO appear to be forming a rounding bottom and recently, have witnessed the recapture of its 200 DMA as well as a noticeable pick-up in volume as we can observe from the Daily chart above. In addition, APTO now finds itself trading above all of its important moving averages 20/50/200 DMA's, which is...
Speculative long on PLX. Accelerated path to approval from FDA. From TA standpoint - charts tried to make a diamond a couple of times, but failed. Will third time be successful to push higher? Opened for 2k shares at .24
TTNP has been catching attention on volume scans this month. Ever since gapping down on October 16, the daily action is noticeably greater than before. But is this a good or bad sign for the penny stock? Currently trading around $0.20. OS is around 17 million so it's not the biggest out there but not the smallest either. Titan Pharmaceuticals is a company that...
Maybe a bull flag or ascending triangle as well. It looks like they're trading above the 200 Day MA, which is bullish for the stock in determining the direction of the trend at times.
LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week? "Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi....
VIVE seems like it can't get out of its own way. Great gap up in the morning but yet again, another red close. Even after reversing, shares are back at penny stock levels. So is it doomed to repeat history or can it find a new bottom? I don't know if anyone really knows for sure just yet. "Viveve’s stock price had a terrible September, dropping more than 57%....
IGXT traded almost the same share volume as previous on Monday with a big red candle. Does this signal weakness for the stock and will it be able to hold levels at or above the previous gap it had from months prior? "The biotech penny stock 's price increased by 61.5% over the month. It started with the company presenting at the H.C Wainwright 21st Annual...